Form 4: Vanda Pharmaceuticals Director Richard W. Dugan Reports Acquisition of Shares and Stock Options

Director Richard W. Dugan reports acquisition of Vanda Pharmaceuticals shares and stock options, signaling potential confidence in the company's future.

Summary

• On May 17, 2024, Richard W. Dugan, a director of Vanda Pharmaceuticals Inc., reported acquiring 20,529 shares of common stock and 37,578 stock options.
• The shares were acquired through a time-based restricted stock unit award (RSU) at a price of $0.
• The stock options have an exercise price of $5.48 and will vest on May 17, 2025, provided continuous service to the issuer.
• Following the reported transaction, Dugan beneficially owns 118,229 shares of common stock and 37,578 stock options.
• The RSU shares will vest on May 17, 2025, contingent upon continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine filing.

Positives

• The acquisition of shares and stock options by a director may signal confidence in the company's future prospects.
• The vesting of the RSU and stock options is tied to continuous service, aligning the director's interests with the long-term success of the company.

Future Outlook

The vesting of the restricted stock units and stock options on May 17, 2025, is contingent upon the director's continuous service to the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.

Key Dates